First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study
about
Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumoursComparison of absolute neutrophil to CD4 lymphocyte values as a marker of immunosuppression in cancer patients on cytotoxic chemotherapyNeutropenia Prediction Based on First-Cycle Blood Counts Using a FOS-3NN Classifier.Pegfilgrastim -- rational drug design for the management of chemotherapy-induced neutropenia.G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients.Canadian supportive care recommendations for the management of neutropenia in patients with cancer.Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis.Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy.Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies.Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer.Dose-dense sequential adriamycin-Paclitaxel-cyclophosphamide chemotherapy is well tolerated and safe in high-risk early breast cancer.Impact of neutropenia on delivering planned chemotherapy for solid tumours.MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis.Discovering Associations of Adverse Events with Pharmacotherapy in Patients with Non-Small Cell Lung Cancer Using Modified Apriori Algorithm.
P2860
Q34858123-C8866CD9-EF5C-44F6-BFEC-CF5D5E1A97CAQ35780507-B42D45E9-8E6C-4C31-8372-00BC1B6081B5Q35791695-CCD3158B-73AF-4B26-B54B-4979E850F713Q36297208-CDECBC92-5E47-41E6-845D-FE8A083D8E97Q36443085-59E698DE-6DA4-43CE-B9FA-774E47F21AD5Q36485208-977789B2-D3B5-4084-958B-67ED8C38248DQ36610747-C27AEF9A-C4FD-4450-B260-C03A4A8309B3Q36762853-AB56C23A-097C-4815-8B3D-13B8EEF484A9Q39698919-A33CC705-1E6B-429C-BE24-2FD5C64FD079Q40307046-3160656B-B39F-4D11-922F-4BDFB7C0B4C9Q46601899-01661457-CC79-4C7A-B6F3-A228C7C9E89DQ46817819-7C485011-933F-4E13-9765-E693F25A5E8CQ47419424-91FCB91C-EB60-49B3-BFC0-350DB27F3C25Q55413674-7397E54F-A3CC-44E2-96B8-73548CFB9706
P2860
First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study
description
2003 nî lūn-bûn
@nan
2003 թուականին հրատարակուած գիտական յօդուած
@hyw
2003 թվականին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
First-cycle absolute neutrophi ...... nt therapy: a validation study
@ast
First-cycle absolute neutrophi ...... nt therapy: a validation study
@en
First-cycle absolute neutrophi ...... nt therapy: a validation study
@nl
type
label
First-cycle absolute neutrophi ...... nt therapy: a validation study
@ast
First-cycle absolute neutrophi ...... nt therapy: a validation study
@en
First-cycle absolute neutrophi ...... nt therapy: a validation study
@nl
prefLabel
First-cycle absolute neutrophi ...... nt therapy: a validation study
@ast
First-cycle absolute neutrophi ...... nt therapy: a validation study
@en
First-cycle absolute neutrophi ...... nt therapy: a validation study
@nl
P2093
P2860
P356
P1476
First-cycle absolute neutrophi ...... nt therapy: a validation study
@en
P2093
Debra Frye
Edgardo Rivera
Gabriel N Hortobagyi
M Haim Erder
Moshe Fridman
P2860
P2888
P304
P356
10.1186/BCR618
P407
P577
2003-01-01T00:00:00Z
P5875
P6179
1036508147